Understanding Biomarker Discordance: MRI and PET Phenotypes Shed Light on Alzheimer’s Pathology
Fuente:
Wiley Open Access
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2024
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867016420919869440 |
|---|---|
| author | Tamil Iniyan Gunasekaran Annie J. Lee Patrick J. Lao Jose Gutierrez Jennifer J. Manly Yian Gu Adam M. Brickman Lawrence S. Honig Badri N. Vardarajan Richard Mayeux |
| author_facet | Tamil Iniyan Gunasekaran Annie J. Lee Patrick J. Lao Jose Gutierrez Jennifer J. Manly Yian Gu Adam M. Brickman Lawrence S. Honig Badri N. Vardarajan Richard Mayeux Tamil Iniyan Gunasekaran Annie J. Lee Patrick J. Lao Jose Gutierrez Jennifer J. Manly Yian Gu Adam M. Brickman Lawrence S. Honig Badri N. Vardarajan Richard Mayeux |
| collection | Wiley Open Access |
| contents | Understanding Biomarker Discordance: MRI and PET Phenotypes Shed Light on Alzheimer’s Pathology Tamil Iniyan Gunasekaran Annie J. Lee Patrick J. Lao Jose Gutierrez Jennifer J. Manly Yian Gu Adam M. Brickman Lawrence S. Honig Badri N. Vardarajan Richard Mayeux Alzheimer's & Dementia AbstractBackgroundPlasma biomarkers for Alzheimer’s disease (AD) are indicators of neuropathological changes. Biomarker cutoffs may not consistently indicate the presence or absence of a pathology. Discrepant biomarker levels are observed in some cognitively normal subjects and patients with clinically diagnosed AD, with some asymptomatic individuals having biomarker evidence of AD pathophysiology and some symptomatic individuals without evidence of AD pathophysiology. The purpose of this study is to understand the discordant biomarker levels among CN and AD using phenotypes from MRI and PET images.MethodWe measured phosphorylated tau 181 (P‐tau181) in plasma from 685 individuals in the Washington Heights Inwood Columbia Aging Project (WHICAP; Mean age = 76.52; women = 64.59%; non‐Hispanic Whites = 29.61%, African Americans = 30.62%; Caribbean Hispanics = 37.30%) and characterized them as biomarker positive based on a ptau181 cutoff of 2.648 pg/mL: 556 cognitively normal (CN, 241 biomarker+), 59 mild cognitively impaired (MCI, 26 biomarker+), and 70 had clinical AD (40 biomarker+). We used MRI (n = 685) and [18F] Florbetaben (FBB) Aβ PET in 167 (24.2%) individuals, and [18F]‐MK‐6420 tau PET 23 (3.36%) individuals) to compare white matter hyperintensity volume (WMH), hippocampus volume, number of silent brain infarcts (SBI), Aβ standard uptake value ratios (SUVR), and tau SUVR among the six biomarker groups (CN‐, CN+, MCI‐, MCI+, AD‐, AD+) with ANCOVA model adjusting for age, sex, and ethnicity.ResultThe AD+ group had larger WMH volume (P = 2.81×10−26), smaller hippocampus volume (P = 5.34×10−04), higher Aβ SUVR (P = 2.26×10−03) and tau SUVR (P = 8.11×10−04) compared to the CN‐. The AD‐ group had larger WMH volumes (P = 1.96×10−04) and smaller hippocampal volume (P = 0.039) to CN‐. When compared to the AD‐ group, the AD+ group had larger WMH volume (P = 4.34×10−03). The CN+ group had a larger WMH volume (P = 4.17×10−03) and smaller hippocampal volume (P = 4.13×10−05) than CN‐ group. Both MCI+ (P = 0.048) and MCI‐ (P = 0.022) groups showed smaller hippocampal volume compared with the CN‐ group. Except for hippocampal volume, no other phenotypes demonstrated statistical significance in the MCI+ and MCI‐ groups.ConclusionMRI and PET phenotypes exhibited a strong association with pathophysiological changes in the AD+ group. Specifically, MRI phenotypes such as WMH volume and hippocampal volume could be instrumental in characterizing AD pathophysiology, even with discrepancies in biomarker profiles. 10.1002/alz.095708 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/alz.095708 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_alz_095708 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Understanding Biomarker Discordance: MRI and PET Phenotypes Shed Light on Alzheimer’s Pathology Tamil Iniyan Gunasekaran Annie J. Lee Patrick J. Lao Jose Gutierrez Jennifer J. Manly Yian Gu Adam M. Brickman Lawrence S. Honig Badri N. Vardarajan Richard Mayeux Alzheimer's & Dementia Understanding Biomarker Discordance: MRI and PET Phenotypes Shed Light on Alzheimer’s Pathology Tamil Iniyan Gunasekaran Annie J. Lee Patrick J. Lao Jose Gutierrez Jennifer J. Manly Yian Gu Adam M. Brickman Lawrence S. Honig Badri N. Vardarajan Richard Mayeux Alzheimer's & Dementia AbstractBackgroundPlasma biomarkers for Alzheimer’s disease (AD) are indicators of neuropathological changes. Biomarker cutoffs may not consistently indicate the presence or absence of a pathology. Discrepant biomarker levels are observed in some cognitively normal subjects and patients with clinically diagnosed AD, with some asymptomatic individuals having biomarker evidence of AD pathophysiology and some symptomatic individuals without evidence of AD pathophysiology. The purpose of this study is to understand the discordant biomarker levels among CN and AD using phenotypes from MRI and PET images.MethodWe measured phosphorylated tau 181 (P‐tau181) in plasma from 685 individuals in the Washington Heights Inwood Columbia Aging Project (WHICAP; Mean age = 76.52; women = 64.59%; non‐Hispanic Whites = 29.61%, African Americans = 30.62%; Caribbean Hispanics = 37.30%) and characterized them as biomarker positive based on a ptau181 cutoff of 2.648 pg/mL: 556 cognitively normal (CN, 241 biomarker+), 59 mild cognitively impaired (MCI, 26 biomarker+), and 70 had clinical AD (40 biomarker+). We used MRI (n = 685) and [18F] Florbetaben (FBB) Aβ PET in 167 (24.2%) individuals, and [18F]‐MK‐6420 tau PET 23 (3.36%) individuals) to compare white matter hyperintensity volume (WMH), hippocampus volume, number of silent brain infarcts (SBI), Aβ standard uptake value ratios (SUVR), and tau SUVR among the six biomarker groups (CN‐, CN+, MCI‐, MCI+, AD‐, AD+) with ANCOVA model adjusting for age, sex, and ethnicity.ResultThe AD+ group had larger WMH volume (P = 2.81×10−26), smaller hippocampus volume (P = 5.34×10−04), higher Aβ SUVR (P = 2.26×10−03) and tau SUVR (P = 8.11×10−04) compared to the CN‐. The AD‐ group had larger WMH volumes (P = 1.96×10−04) and smaller hippocampal volume (P = 0.039) to CN‐. When compared to the AD‐ group, the AD+ group had larger WMH volume (P = 4.34×10−03). The CN+ group had a larger WMH volume (P = 4.17×10−03) and smaller hippocampal volume (P = 4.13×10−05) than CN‐ group. Both MCI+ (P = 0.048) and MCI‐ (P = 0.022) groups showed smaller hippocampal volume compared with the CN‐ group. Except for hippocampal volume, no other phenotypes demonstrated statistical significance in the MCI+ and MCI‐ groups.ConclusionMRI and PET phenotypes exhibited a strong association with pathophysiological changes in the AD+ group. Specifically, MRI phenotypes such as WMH volume and hippocampal volume could be instrumental in characterizing AD pathophysiology, even with discrepancies in biomarker profiles. 10.1002/alz.095708 http://creativecommons.org/licenses/by/4.0/ |
| title | Understanding Biomarker Discordance: MRI and PET Phenotypes Shed Light on Alzheimer’s Pathology |
| topic | Alzheimer's & Dementia |
| url | https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.095708 |